

Ramucirumab REVEL


PRELIMINARY SCORE

CURATIVE



NON-CURATIVE

OS



ADJUSTMENTS

Quality of life



No QoL benefit

Serious and disabling adverse effects



Other adjustments



Ramucirumab REVEL

FINAL SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE

1




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Thoracic Malignancies

Therapeutic Indication: In combination with docetaxel for the treatment of adult patients with locally advanced or metastatic NSCLC with disease progression after platinum-based chemotherapy

Experimental Arm: Ramucirumab + Docetaxel

Control Arm: Docetaxel + placebo



